4-氰基-3-氟苯硼酸 | 843663-18-3

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯硼酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氰基-3-氟苯硼酸
• 中文别名: 3-氟-4-氰基苯硼酸；4-氰基-3-氟苯基硼酸；3-氟-4-氰基苯硼；3-氟-4-腈基苯硼酸
• 英文名称: (4-cyano-3-fluorophenyl)boronic acid
• 英文别名: 3-fluoro-4-cyanophenylboronic acid；4-cyano-3-fluorobenzeneboronic acid；4-Cyano-3-fluorophenylboronic acid
• CAS: 843663-18-3
• 化学式: C₇H₅BFNO₂
• mdl: MFCD03411549
• 分子量: 164.932
• InChiKey: DECWLXUOZUMPBF-UHFFFAOYSA-N

物化性质

• 熔点：
  362-366
• 沸点：
  354.4±52.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)
• 溶解度：
  溶于甲醇
• 稳定性/保质期：

  按规定使用和贮存的不会分解，避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.59
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.2
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2931900090
• 危险品运输编号：
  3439
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  请将药品存放在密闭、阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Cyano-3-fluorophenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Cyano-3-fluorophenylboronic acid
CAS number: 843663-18-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H5BFNO2
Molecular weight: 164.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氰基-3-氟苯硼酸 在 copper(l) iodide 、 N-碘吗啉氢碘酸盐 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 2-氟-4-碘苯腈
  参考文献：
  名称：

  一种实用的和一般本位使用的芳基硼酸的碘化Ñ -iodomorpholinium碘（NIMI）作为一种新的碘化剂：轻度和区域选择性合成芳基碘的†

  摘要：

  为A温和高效的协议本位的芳基硼酸使用-iodination Ñ -iodomorpholinium碘（NIMI）产生原位从吗啉和分子碘作为一种新型的碘化剂已经研制成功。观察到添加催化量的碘化铜可以促进碘化反应的速率提高，并且取决于硼酸的性质，可以显着提高产率。机理研究表明，取决于基材的性质，经典的ipso取代或铜催化的碘脱硼化途径总体上主导了目前的碘化反应。诸如温和的反应条件，操作简便，高至优异的收率，优异的官能团相容性和较低的催化剂载量等特征使该方法潜在地可用于有机合成中。

  DOI：

  10.1039/c5ra18820b
• 作为产物：
  描述：

  2-氟-4-溴苯腈 在 双二甲胺基乙基醚 、 异丙基氯化镁 、 硼酸三甲酯 作用下， 以 四氢呋喃 为溶剂， 以78%的产率得到4-氰基-3-氟苯硼酸
  参考文献：
  名称：

  使用i-PrMgCl-双[2-（N，N-二甲基氨基）乙基]醚络合物对带有敏感官能团的芳族卤化物进行非低温I / Br-Mg交换。

  摘要：

  [反应：见正文]在环境温度下，在双[2-（N，N-二甲基氨基）乙基]醚存在下，对带有敏感羧酸酯和氰基的碘代和溴代芳烃与异丙基氯化镁进行选择性卤化物-镁交换，得到相应的格氏试剂。使新形成的反应性格氏试剂与亲电子试剂如硼酸三甲酯反应，以良好或优异的产率得到芳基硼酸。

  DOI：

  10.1021/ol052704p

文献信息

• [EN] N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF<br/>[FR] N-CYCLOPROPYL-N-PIPÉRIDINYL-AMIDES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014019967A1

  公开（公告）日：2014-02-06

  The present invention relates to compounds of general formula (I), wherein R1, LP, HetAr1, (Het)Ar2 and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式（I）的化合物，其中R1、LP、HetAr1、（Het）Ar2和n如申请中所定义，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。
• 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1
  作者：Fangrui Wu、Chao Zhou、Yuan Yao、Liping Wei、Zizhen Feng、Lisheng Deng、Yongcheng Song

  DOI：10.1021/acs.jmedchem.5b01361

  日期：2016.1.14

  overexpression. We report the design, synthesis, and structure–activity relationships of 3-(piperidin-4-ylmethoxy)pyridine containing compounds as potent LSD1 inhibitors with Ki values as low as 29 nM. These compounds exhibited high selectivity (>160×) against related monoamine oxidase A and B. Enzyme kinetics and docking studies suggested they are competitive inhibitors against a dimethylated H3K4 substrate

  组蛋白赖氨酸残基的甲基化在基因表达调节以及癌症起始中起重要作用。赖氨酸特异性脱甲基酶1（LSD1）负责维持组蛋白H3赖氨酸4（H3K4）的平衡甲基化水平。由于甲基化的H3K4或LSD1过表达的重要功能，LSD1是某些癌症的药物靶标。我们报告了作为有效LSD1抑制剂的含有3-（哌啶-4-基甲氧基）吡啶的化合物（与K i的设计，合成和结构-活性关系）值低至29 nM。这些化合物对相关的单胺氧化酶A和B表现出高选择性（> 160x）。酶动力学和对接研究表明它们是针对二甲基化H3K4底物的竞争性抑制剂，并提供了可能的结合方式。有效的LSD1抑制剂可以增加细胞H3K4甲基化并强烈抑制EC 50值低至280 nM的几种白血病和实体瘤细胞的增殖，而对正常细胞的作用却微不足道。
• [EN] TRPV4 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV4
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2018055527A1

  公开（公告）日：2018-03-29

  The present invention relates to pyrrolidine sulfonamide analogs (I), pharmaceutical compositions containing them and their use as TRPV4 antagonists.

  本发明涉及吡咯烷磺酰胺类似物(I)、含有它们的药物组合物及其作为TRPV4拮抗剂的应用。
• [EN] 6-PHENYL- OR 6-(PYRIDIN-3-YL)INDAZOLE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS DE 6-PHÉNYL OU 6-(PYRIDIN-3-YL)INDAZOLE ET PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2015112445A1

  公开（公告）日：2015-07-30

  Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  公式(I)的化合物以及药用可接受的盐、酯、酰胺或放射性标记形式，其中R1、R2、R3、R4、R5、R6和X如说明书所述，可用于治疗通过Tropomysin受体激酶（Trk）预防或改善的状况或疾病。公开了制造这些化合物的方法。还公开了公式(I)化合物的药物组合物，以及使用这些化合物和组合物的方法。
• 6 Phenyl or 6 Pyridin 3 YL Indazole Derivatives and Methods of Use
  申请人：ABBVIE INC.

  公开号：US20160376240A1

  公开（公告）日：2016-12-29

  Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  公式(I)的化合物以及药用可接受的盐、酯、酰胺或放射性标记形式，其中R1、R2、R3、R4、R5、R6和X如说明书中所定义，可用于治疗通过Tropomysin受体激酶（Trk）预防或改善的状况或疾病。公开了制备这些化合物的方法。还公开了公式(I)化合物的药物组合物，以及使用这些化合物和组合物的方法。